ANI Pharma and IDT Australia collaborate on US generics

Home/Pharma News | Posted 28/08/2015 post-comment0 Post your comment

US-based brand-name and generic drugmaker ANI Pharmaceuticals (ANI) announced on 12 August 2015 that it had entered into a collaboration with generics company IDT Australia (IDT) to commercialize up to 18 previously marketed US generics.

Australia flag V13C29

The news follows IDT’s announcement in April 2015 that the US Food and Drug Administration (FDA) had accepted the transfer of ownership of 23 generics to the Australia-based company [1].

ANI has paid US$1 million for the exclusive rights to commercialize the 18 generics in North America. ANI will also share in an undisclosed percentage of net profits upon commercialization. The total current annual US market for these products is estimated to be worth US$538 million, according to IMS Health.

IDT expects to file a CBE-30 (changes being effected) for the first generic drug product in the fourth quarter of 2015.

ANI has already acquired 53 generics from Teva Pharmaceuticals [2, 3]. This deal will further expand ANI’s generics portfolio.

Related article
Mergers between Watson/Actavis and ANI Pharma/BioSante

References
1. GaBI Online - Generics and Biosimilars Initiative. IDT Australia gets FDA nod for 23 generics [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Aug 28]. Available from: www.gabionline.net/Generics/News/IDT-Australia-gets-FDA-nod-for-23-generics
2. GaBI Online - Generics and Biosimilars Initiative. ANI Pharmaceuticals acquires 22 generics from Teva [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Aug 28]. Available from: www.gabionline.net/Generics/News/ANI-Pharmaceuticals-acquires-22-generics-from-Teva
3. GaBI Online - Generics and Biosimilars Initiative. ANI Pharmaceuticals acquires 31 generics from Teva [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Aug 28]. Available from: www.gabionline.net/Generics/News/ANI-Pharmaceuticals-acquires-31-generics-from-Teva

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.

Source: ANI Pharma

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010